ARC Regulatory: Leading Innovation in Life Sciences Technology

ARC Regulatory, sponsor of this year’s Belfast Telegraph IT Awards Development Team of the Year, is redefining how technology drives progress in the life sciences sector. From its base in Belfast, the company is leading the global charge in combining scientific rigour, regulatory expertise, and artificial intelligence to raise the standards of performance and compliance across healthcare.

A specialist consultancy serving the precision medicine and in vitro diagnostics sectors, ARC Regulatory offers deep expertise in diagnostics CRO and sponsor delegation, laboratory services, and pharma tech solutions. Headquartered in Belfast’s Titanic Quarter, the company partners with clients from early-stage clinical development through to registrational global trials. By uniting regulatory strategy, rigorous clinical operations and deep domain expertise, ARC helps innovators bring transformative healthcare solutions to global markets with efficiency and confidence.

At the core of ARC’s technology ecosystem is ARC360®, a platform that has revolutionised how life sciences organisations manage regulatory compliance in precision medicine trials. ARC360® accelerates submissions, enhances collaboration, and provides sponsors with a unified, transparent view of every study, team, and market. The result is a faster, more coordinated process for bringing innovative therapies to patients worldwide. Built on extensive regulatory experience, the platform enables companies to reduce study start-up times by months, cutting costs and easing the burden on clinical teams. By centralising global submissions, ARC360® ensures both efficiency and compliance across jurisdictions, empowering organisations to initiate and manage their trials with confidence.

Recent upgrades have made ARC360® even more advanced, introducing real-time project oversight, intuitive dashboards, and curated regulatory intelligence spanning more than 50 countries. These enhancements equip clinical and regulatory teams with the insight and agility they need to stay aligned, informed, and compliant from study design through to approval.

ARC’s latest technological leap is its new generation of Pharma AI, developed specifically for the complex demands of pharmaceutical innovation. The company will begin initial trials and testing in the coming months, demonstrating how its AI systems can enhance decision-making in environments where precision and reliability are critical. Rather than replacing human expertise, ARC’s technology amplifies it using intelligent automation and deep regulatory insight to accelerate progress across the entire clinical development lifecycle.

“AI will only succeed in life sciences if it’s safe, transparent, and compliant,” says Seamus Kearney, Founder and CEO of ARC Regulatory. “Our mission is to develop technology that doesn’t just make processes faster but makes them stronger. AI that supports precision, reliability, and regulatory excellence.”

ARC’s growth reflects its ongoing commitment to innovation, investment, and regional development. In July 2025, the company announced a new office hub in Derry~Londonderry, representing a £250,000 investment, following the launch of its £3 million state-of-the-art laboratory facilities in Belfast earlier in the year. These strategic developments underscore ARC’s dedication to advancing both regional innovation and global impact.

ARC Regulatory continues to redefine what’s possible in life sciences technology. Guided by scientific and regulatory excellence, the company is proving that innovation, when built on integrity and intelligence, can accelerate access to safer, smarter personalised interventions for patients worldwide.